After decades of work, the biopharma industry has begun proving that artificial-intelligence-designed molecules can leapfrog traditionally developed counterparts on the journey to human testing. And now, drugmakers realize they can shave months and more off early-stage research by incorporating AI. The conclusion reached by a panel at a recent biotech event is that AI in drug discovery is starting to grow up. This blog provides a summary of expert insights on the maturity of AI and how it impacts the ability of researchers to pursue new opportunities. Read the blog to hear what thought leaders have to say on what it takes to keep AI moving forward in biopharma.